Nasdaq · CIK 0001894562
PRME Prime Medicine, Inc.
Insider trading from SEC Form 4. Last filing Aug 5, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Signals
Open-market buys and sells at Prime Medicine, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Gv 2021 Gp, L.l.c. owner buy | $5.0M 1,500,000 shares | +85% | - | |
| 57Moderate | ARCH Venture Partners X, LLC owner buy | $10.0M 3,030,300 shares | +95% | - | |
| 57Moderate | ARCH Venture Partners XII, LLC owner buy | $10.0M 3,030,300 shares | +95% | - | |
| 0Weak | David R. Liu owner buy | $45k 21,000 shares | +0% | - | |
| 0Weak | David R. Liu owner buy | $31k 21,000 shares | +0% | - | |
| 0Weak | David R. Liu owner buy | $34k 21,000 shares | +0% | - | |
| 38Weak | Richard Brudnick Chief Business Officer buy | $24k 20,000 shares | - | - | |
| 48Moderate | Ann L. Lee Chief Technical Officer buy | $113k 100,000 shares | - | - | |
| 59Moderate | Allan Reine Chief Executive Officer buy | $147k 125,000 shares | - | - |
Transactions
The last 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | Kaye I Foster-Cheek director | DDisposition to issuer Stock Option (right to buy)derivative | -13,510 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | DDisposition to issuer Stock Option (right to buy)derivative | -16,083 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | DDisposition to issuer Stock Option (right to buy)derivative | -13,510 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Thomas Cahill director | DDisposition to issuer Stock Option (right to buy)derivative | -39,062 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Gv 2021 Gp, L.l.c. owner | POpen-market purchase Common Stockindirect: By GV 2021, L.P. | +1,500,000 | $3.30 | $5.0M | 3,262,440 | Aug 5, 2025 |
| Aug 1, 2025 | Thomas Cahill director | AGrant or award Stock Option (right to buy)derivative | +39,062 | - | - | 39,062 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | AGrant or award Stock Option (right to buy)derivative | +13,510 | - | - | 13,510 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | AGrant or award Stock Option (right to buy)derivative | +13,510 | - | - | 13,510 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | AGrant or award Stock Option (right to buy)derivative | +16,083 | - | - | 16,083 | Aug 5, 2025 |
| Aug 1, 2025 | Thomas Cahill director | DDisposition to issuer Stock Option (right to buy)derivative | -45,000 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | DDisposition to issuer Stock Option (right to buy)derivative | -90,498 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | DDisposition to issuer Stock Option (right to buy)derivative | -9,006 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | DDisposition to issuer Stock Option (right to buy)derivative | -9,006 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | AGrant or award Stock Option (right to buy)derivative | +9,006 | - | - | 9,006 | Aug 5, 2025 |
| Aug 1, 2025 | Thomas Cahill director | AGrant or award Stock Option (right to buy)derivative | +45,000 | - | - | 45,000 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | AGrant or award Stock Option (right to buy)derivative | +90,498 | - | - | 90,498 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | AGrant or award Stock Option (right to buy)derivative | +9,006 | - | - | 9,006 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | DDisposition to issuer Stock Option (right to buy)derivative | -39,062 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | DDisposition to issuer Stock Option (right to buy)derivative | -6,254 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | DDisposition to issuer Stock Option (right to buy)derivative | -39,062 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | AGrant or award Stock Option (right to buy)derivative | +6,254 | - | - | 6,254 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | AGrant or award Stock Option (right to buy)derivative | +39,062 | - | - | 39,062 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | AGrant or award Stock Option (right to buy)derivative | +39,062 | - | - | 39,062 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | DDisposition to issuer Stock Option (right to buy)derivative | -45,000 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | DDisposition to issuer Stock Option (right to buy)derivative | -45,000 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | DDisposition to issuer Stock Option (right to buy)derivative | -90,498 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | Wendy Chung director | AGrant or award Stock Option (right to buy)derivative | +45,000 | - | - | 45,000 | Aug 5, 2025 |
| Aug 1, 2025 | Carman Alenson See Remarks | AGrant or award Stock Option (right to buy)derivative | +90,498 | - | - | 90,498 | Aug 5, 2025 |
| Aug 1, 2025 | Kaye I Foster-Cheek director | AGrant or award Stock Option (right to buy)derivative | +45,000 | - | - | 45,000 | Aug 5, 2025 |
| Aug 1, 2025 | ARCH Venture Partners XII, LLC owner | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +3,030,300 | $3.30 | $10.0M | 6,230,300 | Aug 1, 2025 |
| Aug 1, 2025 | ARCH Venture Partners X, LLC owner | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +3,030,300 | $3.30 | $10.0M | 6,230,300 | Aug 1, 2025 |
| Jun 23, 2025 | David R. Liu owner | POpen-market purchase Common Stock10b5-1 | +21,000 | $2.16 | $45k | 20,219,945 | Jun 23, 2025 |
| Jun 16, 2025 | David R. Liu owner | POpen-market purchase Common Stock10b5-1 | +21,000 | $1.49 | $31k | 20,198,945 | Jun 16, 2025 |
| Jun 11, 2025 | David R. Liu owner | POpen-market purchase Common Stock10b5-1 | +21,000 | $1.60 | $34k | 20,177,945 | Jun 12, 2025 |
| Jun 4, 2025 | Thomas Cahill director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | Wendy Chung director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | Kaye I Foster-Cheek director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | Michael Aaron Kelly director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | Jeffrey D Marrazzo director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | Robert Nelsen director, owner | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| Jun 4, 2025 | David P Schenkein director | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Jun 5, 2025 |
| May 21, 2025 | Ann L. Lee Chief Technical Officer | POpen-market purchase Common Stock | +100,000 | $1.13 | $113k | 100,000 | May 22, 2025 |
| May 21, 2025 | Allan Reine Chief Executive Officer | POpen-market purchase Common Stock | +125,000 | $1.18 | $147k | 125,000 | May 22, 2025 |
| May 20, 2025 | Richard Brudnick Chief Business Officer | POpen-market purchase Common Stock | +20,000 | $1.19 | $24k | 20,000 | May 22, 2025 |
| May 19, 2025 | Jeffrey D Marrazzo director | AGrant or award Stock Option (right to buy)derivative | +800,000 | $0.00 | $0 | 800,000 | May 19, 2025 |
| May 19, 2025 | Allan Reine Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | May 19, 2025 |
| May 8, 2025 | Keith Michael Gottesdiener See Remarks | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 300,000 | May 12, 2025 |
| May 8, 2025 | Ann L. Lee Chief Technical Officer | AGrant or award Stock Option (right to buy)derivative | +80,416 | $0.00 | $0 | 241,248 | May 12, 2025 |
| May 8, 2025 | Allan Reine Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 850,000 | May 12, 2025 |
| Feb 28, 2025 | Keith Michael Gottesdiener See Remarks | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Mar 4, 2025 |
| Feb 27, 2025 | Carman Alenson See Remarks | AGrant or award Stock Option (right to buy)derivative | +90,500 | $0.00 | $0 | 90,500 | Mar 3, 2025 |
| Feb 27, 2025 | Richard Brudnick Chief Business Officer | AGrant or award Stock Option (right to buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 3, 2025 |
| Feb 27, 2025 | Jeremy Duffield Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Mar 3, 2025 |
| Feb 27, 2025 | Meredith Goldwasser SVP, Strategy & Corporate Ops. | AGrant or award Stock Option (right to buy)derivative | +90,500 | $0.00 | $0 | 90,500 | Mar 3, 2025 |
| Feb 27, 2025 | Ann L. Lee Chief Technical Officer | AGrant or award Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Mar 3, 2025 |
| Dec 5, 2024 | Richard Brudnick Chief Business Officer | AGrant or award Stock Option (right to buy)derivative | +19,300 | $0.00 | $0 | 57,900 | Dec 9, 2024 |
| Dec 5, 2024 | Keith Michael Gottesdiener See Remarks | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 200,000 | Dec 9, 2024 |
| Dec 5, 2024 | Allan Reine Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 775,000 | Dec 9, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- ARCH Venture Partners X, LLCowner
- ARCH Venture Partners XII, LLCowner
- Carman AlensonSee Remarks
- Richard BrudnickChief Business Officer
- Thomas Cahilldirector
- Wendy Chungdirector
- Jeremy DuffieldChief Scientific Officer
- Kaye I Foster-Cheekdirector
- Gv 2021 Gp, L.l.c.owner
- Meredith GoldwasserSVP, Strategy & Corporate Ops.
- Keith Michael GottesdienerSee Remarks
- Michael Aaron Kellydirector
- Ann L. LeeChief Technical Officer
- David R. Liuowner
- Jeffrey D Marrazzodirector
- Robert Nelsenowner, director
- Allan ReineChief Executive Officer
- David P Schenkeindirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.